Literature DB >> 6119592

Biphasic influence of a 8 alpha-amino ergoline, CU 32-085, on striatal dopamine synthesis and turnover in vivo in the rat.

A Enz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6119592     DOI： 10.1016/0024-3205(81)90494-x

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  10 in total

1.  Evidence that blockade of post-synaptic 5-HT1 receptors elicits feeding in satiated rats.

Authors:  C T Dourish; M L Clark; A Fletcher; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Classification of drugs according to receptor binding profiles.

Authors:  A Closse; W Frick; A Dravid; G Bolliger; D Hauser; A Sauter; H J Tobler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

3.  Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.

Authors:  H Biesemeyer; H P Ludin; E Ringwald
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

4.  Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.

Authors:  H Baas; E Schneider; P A Fischer; G Japp
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

5.  On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behaviour in rats.

Authors:  L Ståhle; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Authors:  R Markstein; A Enz; J M Vigouret; A Jaton; A Closse; U Briner; P Gull
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  Mesulergine in early Parkinson's disease: a double blind controlled trial.

Authors:  E Dupont; B Mikkelsen; J Jakobsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

8.  Mesulergine and pergolide in previously untreated Parkinson's disease.

Authors:  A Wright; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-04       Impact factor: 10.154

9.  Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.

Authors:  E Schneider; H Baas; P A Fischer; G Japp
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

10.  Dopaminergic properties of mesulergine (CU 32-085) and its metabolites.

Authors:  A Enz; P Donatsch; R Nordmann
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.